{"slideshow_credits": null, "snippet": "The new drug, Iclusig from Ariad Pharmaceuticals, has performed better in some patients than existing treatments for chronic myeloid leukemia.", "abstract": "Food and Drug Administration approves new drug, Iclusig from Ariad Pharmaceuticals, which has performed better in some patients than existing treatments for chronic myeloid leukemia.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/12/15/business/fda-gives-early-approval-to-leukemia-drug-iclusig.html", "lead_paragraph": "The new drug, Iclusig from Ariad Pharmaceuticals, has performed better in some patients than existing treatments for chronic myeloid leukemia.", "headline": {"seo": "F.D.A. Gives Early Approval to Leukemia Drug Iclusig", "main": "F.D.A. Gives Early Approval to Drug for Rare Leukemia", "print_headline": "F.D.A. Gives Early Approval To Drug for Rare Leukemia"}, "_id": "50cbc95900315214fbb7f796", "word_count": "722", "multimedia": [], "pub_date": "2012-12-15T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Iclusig (Drug)", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Chronic Myelogenous Leukemia", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Ariad Pharmaceuticals Inc", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "4"}, {"value": "Leukemia", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}